HCL-TECHNOLOGIES
HCL Foundation (HCLF), the Corporate Social Responsibility (CSR) arm of HCL Technologies, today announced the recipients of the fifth edition of HCL Grant in the presence of Padma Bhushan, Mr. Kapil Dev, a legend in the global world of cricket and former captain of the Indian Cricket team.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200227005709/en/
HCL Grant is one of the biggest and most coveted institutionalized CSR grants in India that aims to recognize the rise of the Fifth Estate - the Non-Governmental Organizations (NGOs).
The evening was also graced by Mr. Shiv Nadar, Founder & Chairman, HCL, Ms. Roshni Nadar Malhotra, Vice Chairperson of HCL Technologies and the Chairperson of its CSR committee, and Mr. Prateek Aggarwal, Chief Financial Officer, HCL Technologies along with senior dignitaries, officials, NGO-partners and HCL leadership.
HCL Grant 2020 witnessed three NGOs across the categories of Education, Healthcare and Environment receiving a grant of ₹5 crores each. The remaining six finalists across the three categories also received ₹25 lakhs each, taking the overall Grant to ₹16.5 crore.
The finalists and the winners were selected by an eminent jury, which was chaired by Ms. Robin Abrams, Member of the Board, HCL Technologies.
Recipients of HCL Grant 2020:
-
Environment- The 2020 HCL Grant winner in this category is Under The Mango Tree Society.
Project Location: 4 districts (Gujarat, Maharashtra and Madhya Pradesh) -
Healthcare- The 2020 HCL Grant winner in this category is Operation ASHA.
Project Location: Kullu (Himachal Pradesh) -
Education- The 2020 HCL Grant winner in this category is Bal Raksha Bharat.
Project Location: Leh (Ladakh) and Budgam (J&K)
“It is extremely important to bring equal opportunities to people coming from every strata of the society. Health, Education and Environment are one of the most important pillars towards India’s development goals and I am highly impressed with the kind of impact these NGOs are bringing in the rural communities. Also, the robustness of the identification process is something I have not witnessed before. I congratulate both HCL as well the winners and finalists for the phenomenal work they are doing in their respective fields,” Mr. Kapil Dev said while addressing the audience at the event.
Excluding the current grant, HCL Grant has already disbursed ₹51.5 crores (US$ 7.4Mn) to benefit nearly 500,000 people and its supported projects aim to cover over a million people spread across 7,500 villages across 13 States and one Union Territory in the country.
“HCL Foundation is our long-term commitment for social development and today it has improved over 1.5 million lives across our country. Our collaborative model allows us to support communities with critical concerns needing immediate attention and HCL Grant is a prime example of the same. I am proud to say that today the improvements we have been able to drive together with the HCL Grant partner NGOs is not just in terms of immediate impact on beneficiary lives, but also about ensuring long-term sustainable change by influencing state and government policies,” said Ms. Roshni Nadar Malhotra, Vice-Chairperson, HCL Technologies and Chairperson, CSR Committee, HCL Technologies.
Ms. Nidhi Pundhir, Director HCL Foundation, said, “This is a very special year for us as we complete half a decade of empowering the NGOs that are committed to ushering change. This annual HCL Grant event is a culmination of our year-long efforts to identify partners who have the potential to achieve the maximum impact through their social development projects.. We are truly honored to have received applications from all parts of the country and my heartiest congratulations to the winning NGOs for giving us the opportunity to partner with them and support ideas for impactful positive change.”
HCL Foundation also released the compendium of the previous year’s finalists and winning NGOs, named “Fifth Estate – NGOs Transforming Rural India in Environment, Health and Education”.
For more information please visit www.hclfoundation.org/hcl-grant .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200227005709/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom